These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25113945)

  • 1. Recently targeted kinases and their inhibitors-the path to clinical trials.
    Knapp S; Sundström M
    Curr Opin Pharmacol; 2014 Aug; 17():58-63. PubMed ID: 25113945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is target validation all we need?
    Frigault MM; Barrett JC
    Curr Opin Pharmacol; 2014 Aug; 17():81-6. PubMed ID: 25261632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mini-review: bmx kinase inhibitors for cancer therapy.
    Jarboe JS; Dutta S; Velu SE; Willey CD
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):228-38. PubMed ID: 23198769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical biology approaches to target validation in cancer.
    Blagg J; Workman P
    Curr Opin Pharmacol; 2014 Aug; 17():87-100. PubMed ID: 25175311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
    Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
    Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.
    Alain T; Sonenberg N; Topisirovic I
    Oncotarget; 2012 Dec; 3(12):1491-2. PubMed ID: 23455427
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
    Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
    Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in targeting signal transduction pathways.
    McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN
    Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinase inhibitors as potential agents in the treatment of multiple myeloma.
    Abramson HN
    Oncotarget; 2016 Dec; 7(49):81926-81968. PubMed ID: 27655636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 14. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-kinase inhibitors, AURKs and cancer.
    Cicenas J; Cicenas E
    Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of PI3K inhibitors: lessons learned from early clinical trials.
    Rodon J; Dienstmann R; Serra V; Tabernero J
    Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.
    Lorusso PM; Eder JP
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1013-28. PubMed ID: 18549338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.